141 Spam-Free Article(s) Found
Article Searches
Bvf Inc Buys Ironwood Pharmaceuticals Inc, Merus NV, Xencor Inc, Sells Array BioPharma Inc, ... http://www.gurufocus.com/news/678059/bvf-inc-buys-ironwood-pharmaceuticals-inc-merus-nv-xencor-inc-sells-array-biopharma-inc-cytomx-therapeutics-inc-anaptysbio-inc May 07, 2018 - Bvf Inc Buys Ironwood Pharmaceuticals Inc, Merus NV, Xencor Inc, Sells Array BioPharma Inc, CytomX Therapeutics Inc, AnaptysBio Inc, Stocks: CRVS,IMDZ,PIRS,FWP,VSTM,PTGX,IRWD,MRUS,XNCR,RCUS,A, release date:May 07, 2018
JF's Core Biotech Buys #14: Introducing Our Final 2 Positions & Taking Advantage Of Weakness In The I-O Space https://seekingalpha.com/article/4170858-jfs-core-biotech-buys-14-introducing-final-2-positions-and-taking-advantage-weakness-o-space?source=feed_all_articles May 07, 2018 - The M&A theme appears set to continue in the spotlight this year, with Gilead to put cash to work and Takeda likely to come to terms with Shire.President Trump´s drug pricing speech is expected soon a
Reader Inquiry: Is Recent Weakness In Array BioPharma Warranted? https://seekingalpha.com/article/4170365-reader-inquiry-recent-weakness-array-biopharma-warranted?source=feed_all_articles May 06, 2018 - The stock has performed admirably since my initial article. However, it´s currently the biggest loser in the Core Biotech model account. I provide a recap of the bullish thesis and recent developments
Will Tinder Gold Drive Match Group's (MTCH) Q1 Earnings? http://www.zacks.com/stock/news/302408/will-tinder-gold-drive-match-groups-mtch-q1-earnings?cid=CS-ZC-FT-302408 May 04, 2018 - Match Group's (MTCH) first-quarter 2018 earnings to benefit from steady market traction of apps like Tinder, which are driving higher subscriber growth.
What's in the Cards for Inovio (INO) This Earnings Season? http://www.zacks.com/stock/news/302456/whats-in-the-cards-for-inovio-ino-this-earnings-season?cid=CS-ZC-FT-302456 May 04, 2018 - Inovio's (INO) most advanced pipeline candidate, VGX-3100's progress remains in focus. However, lack of an approved product in the company's portfolio is a dampener.
What's in Store for Penumbra (PEN) This Earnings Season? http://www.zacks.com/stock/news/302451/whats-in-store-for-penumbra-pen-this-earnings-season?cid=CS-ZC-FT-302451 May 04, 2018 - Penumbra (PEN) deepens its focus on driving innovation, ramping up production and expanding geographies.
Envision Healthcare (EVHC) to Report Q1 Earnings: What's Up? http://www.zacks.com/stock/news/302287/envision-healthcare-evhc-to-report-q1-earnings-whats-up?cid=CS-ZC-FT-302287 May 04, 2018 - Envision Healthcare's (EVHC) Q1 earnings should see an upside from higher revenues at both its segments.
What's in Store for Celldex (CLDX) This Earnings Season? http://www.zacks.com/stock/news/302186/whats-in-store-for-celldex-cldx-this-earnings-season?cid=CS-ZC-FT-302186 May 03, 2018 - With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus is on its immuno-oncology pipeline.
What's in the Cards for Geron (GERN) This Earnings Season? http://www.zacks.com/stock/news/302174/whats-in-the-cards-for-geron-gern-this-earnings-season?cid=CS-ZC-FT-302174 May 03, 2018 - With no approved product in Geron's (GERN) portfolio, investor focus continues to remain on its sole pipeline candidate, imetelstat, ahead of the first-quarter earnings release.
Lucky Seven: An Introduction To My Top Biotechnology Picks https://seekingalpha.com/article/4169005-lucky-seven-introduction-top-biotechnology-picks?source=feed_all_articles May 03, 2018 - We will initiate coverage on seven biotechnology stocks.These seven companies are primarily picked for their current valuation, pipeline prospects, financial figures, and likelihood of near-term share

Pages: 1234567...15

<Page 2>